Literature DB >> 12931313

Treatment options for osteoarthritis.

Gurkirpal Singh1.   

Abstract

Osteoarthritis (OA) is a debilitating, degenerative disease of the articular cartilage and synovial fluid. Approximately 20 million Americans suffer from this disease for which no cure exists as yet. The primary goals of current OA therapy are centered on controlling pain; improving, preserving, or both, joint function and mobility; and improving health-related quality of life-but not on reversing the disease process. Current treatment options of OA consist of both non-pharmacological and pharmacological modalities. Non-pharmacological therapy that consists of patient education and physical/occupational therapy is a primary component of OA management, either rendered alone or in combination with pharmacological treatment. The several options for pharmacological treatment include acetaminophen, nonspecific NSAIDs, and COX-2 specific inhibitors. Many of these drugs, however, are beset with serious side effects. For patients with severe OA not responsive to medical treatment, nonsurgical interventions such as viscosupplements and injectable compounds that mimic healthy synovial fluid or surgical interventions are two likely options. The former, however, have not been shown unequivocally to be effective. Future treatment modalities for OA are geared toward reversing the disease process and may include disease-modifying drugs and gene therapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12931313

Source DB:  PubMed          Journal:  Surg Technol Int        ISSN: 1090-3941


  4 in total

Review 1.  The problem with NSAIDs: what data to believe?

Authors:  Gayle McKellar; Rajan Madhok; Gurkirpal Singh
Journal:  Curr Pain Headache Rep       Date:  2007-12

2.  Comparative efficacy and safety of mavacoxib and carprofen in the treatment of canine osteoarthritis.

Authors:  M Payne-Johnson; C Becskei; Y Chaudhry; M R Stegemann
Journal:  Vet Rec       Date:  2014-11-27       Impact factor: 2.695

3.  Pedobarography: a novel approach to test the efficacy of treatments for lameness; an experience with mavacoxib in dogs with elbow osteoarthritis.

Authors:  Sergio López; José M Vilar; Mónica Rubio; Joaquín J Sopena; Angelo Santana; Oliver Rodríguez; José A Rodríguez-Altonaga; José M Carrillo
Journal:  BMC Vet Res       Date:  2019-06-11       Impact factor: 2.741

4.  Enflicoxib for canine osteoarthritis: A randomized, blind, multicentre, non-inferiority clinical trial compared to mavacoxib.

Authors:  Marta Salichs; Llorenç Badiella; Patxi Sarasola; Josep Homedes
Journal:  PLoS One       Date:  2022-09-20       Impact factor: 3.752

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.